Barinthus Biotherapeutics plc (BRNS)
NASDAQ: BRNS · IEX Real-Time Price · USD
2.200
+0.150 (7.32%)
At close: May 1, 2024, 4:00 PM
2.270
+0.070 (3.18%)
Pre-market: May 2, 2024, 4:06 AM EDT
Barinthus Biotherapeutics Revenue
In the year 2023, Barinthus Biotherapeutics had annual revenue of $802.00K, a decrease of -98.21%.
Revenue (ttm)
$802.00K
Revenue Growth
-98.21%
P/S Ratio
106.00
Revenue / Employee
$6,169
Employees
130
Market Cap
85.02M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 802.00K | -43.90M | -98.21% |
Dec 31, 2022 | 44.70M | 44.44M | 16,580.22% |
Dec 31, 2021 | 268.00K | -4.55M | -94.44% |
Dec 31, 2020 | 4.82M | -2.02M | -29.57% |
Dec 31, 2019 | 6.85M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Emergent BioSolutions | 1.05B |
Aurora Cannabis | 200.73M |
FONAR | 102.42M |
Neuronetics | 71.35M |
KORU Medical Systems | 28.52M |
Oramed Pharmaceuticals | 1.34M |
Zentek | 25.27K |
GlycoMimetics | 10.00K |
BRNS News
- 1 day ago - Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer - GlobeNewsWire
- 13 days ago - Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections - GlobeNewsWire
- 6 weeks ago - Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments - GlobeNewsWire
- 4 months ago - Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones - GlobeNewsWire
- 4 months ago - New partnership aims to advance vaccine against MERS coronavirus - GlobeNewsWire
- 6 months ago - Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD - GlobeNewsWire
- 6 months ago - Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments - GlobeNewsWire
- 6 months ago - Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer - GlobeNewsWire